#Subcutaneous nivolumab approved by
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
